For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Enliven Therapeutics Inc’s stock clocked out at $16.3, down -2.57% from its previous closing price of $16.73. In other words, the price has decreased by -$2.57 from its previous closing price. On the day, 0.47 million shares were traded. ELVN stock price reached its highest trading level at $16.71 during the session, while it also had its lowest trading level at $15.88.
Ratios:
To gain a deeper understanding of ELVN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.95 and its Current Ratio is at 32.95. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37. On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42. On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 19 ’25 when Lyssikatos Joseph P sold 5,000 shares for $16.84 per share. The transaction valued at 84,206 led to the insider holds 897,688 shares of the business.
Lyssikatos Joseph P bought 5,000 shares of ELVN for $83,400 on Dec 19 ’25. On Dec 17 ’25, another insider, Kintz Samuel, who serves as the Officer of the company, bought 5,000 shares for $16.91 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 967361216 and an Enterprise Value of 490286272.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.38, which has changed by -0.27199644 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $25.37, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -18.77%, while the 200-Day Moving Average is calculated to be -17.76%.
Shares Statistics:
It appears that ELVN traded 612.68K shares on average per day over the past three months and 922360 shares per day over the past ten days. A total of 59.26M shares are outstanding, with a floating share count of 43.26M. Insiders hold about 27.06% of the company’s shares, while institutions hold 77.97% stake in the company. Shares short for ELVN as of 1765756800 were 8111262 with a Short Ratio of 13.24, compared to 1763078400 on 7794126. Therefore, it implies a Short% of Shares Outstanding of 8111262 and a Short% of Float of 19.450001.
Earnings Estimates
Enliven Therapeutics Inc (ELVN) is currently under the scrutiny of 1 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.36 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.96 and -$1.96 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.98, with 7.0 analysts recommending between -$1.55 and -$2.39.
